Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiation Therapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)
Glioblastoma Multiforme is one of the most common, and unfortunately one of the most
aggressive brain tumours in adults with most of the patients recurring and dying of the
disease with a median survival of 16 months from diagnosis.
Current treatment for patients with newly diagnosed Glioblastoma Multiforme (GBM) is safe
maximal surgical resection followed by concomitant conventional Radiation Therapy (RT) delivered
in 6 weeks + Temozolomide (TMZ) followed by TMZ for 6 to 12 cycles.
Recent scientific research has shown that Metformin, a common drug used to treat diabetes
mellitus, may improve the results of the treatment in patients with a variety of cancers,
such as breast, colon, and prostate cancer. Metformin is an attractive and safe medication
to be used in this group of patients because of its very low toxicity.
In our centre the investigators have been using TMZ for 2 weeks prior to a short course (4
weeks) of RT which equivalent to the standard RT of 6 weeks. Temozolomide is used 2 weeks
before RT + TMZ, and this is followed by the 6 to 12 cycles of TMZ. Our results are quiet
encouraging with a median survival of 20 months, and acceptable toxicity.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society